Welcome to LookChem.com Sign In|Join Free

CAS

  • or

32943-25-2

Post Buying Request

32943-25-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

32943-25-2 Usage

Chemical Properties

Pale Yellow Solid

Uses

3-Chloroiminodibenzyl is a metabolite of Desipramine (D290050) and Clomipramine (C587050).

Check Digit Verification of cas no

The CAS Registry Mumber 32943-25-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,2,9,4 and 3 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 32943-25:
(7*3)+(6*2)+(5*9)+(4*4)+(3*3)+(2*2)+(1*5)=112
112 % 10 = 2
So 32943-25-2 is a valid CAS Registry Number.
InChI:InChI=1/C14H12ClN/c15-12-8-7-11-6-5-10-3-1-2-4-13(10)16-14(11)9-12/h1-4,7-9,16H,5-6H2

32943-25-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma-Aldrich

  • (Y0000134)  Clomipramine impurity F  European Pharmacopoeia (EP) Reference Standard

  • 32943-25-2

  • Y0000134

  • 1,880.19CNY

  • Detail
  • USP

  • (1140292)  Clomipramine Related Compound F  United States Pharmacopeia (USP) Reference Standard

  • 32943-25-2

  • 1140292-15MG

  • 14,500.98CNY

  • Detail

32943-25-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-chloro-6,11-dihydro-5H-benzo[b][1]benzazepine

1.2 Other means of identification

Product number -
Other names Clomipramine impurity F

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:32943-25-2 SDS

32943-25-2Synthetic route

3-chloro-5-(3-dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(6,5)azepine
25961-11-9

3-chloro-5-(3-dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(6,5)azepine

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
With potassium hydroxide In methanol Heating;95%
Stage #1: 3-chloro-5-(3-dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(6,5)azepine With Triethoxysilane; sodium triethylborohydride In tert-butyl methyl ether at 80℃; for 6h;
Stage #2: With hydrogenchloride In tert-butyl methyl ether; water at 20℃; for 1h; Reagent/catalyst; Temperature; Concentration; chemoselective reaction;
91%
With triethyl borane; sodium hydroxide In tert-butyl methyl ether at 80℃; for 6h; Inert atmosphere; Sealed tube;86%
Multi-step reaction with 2 steps
1: potassium hydroxide; triethyl borane / tetrahydrofuran / 24 h / 100 °C / Inert atmosphere; Schlenk technique; Sealed tube
2: sodium hydroxide; water / tetrahydrofuran / 1 h / 25 °C / Inert atmosphere; Schlenk technique; Sealed tube
View Scheme
With potassium hydroxide In toluene at 85℃; for 6h;
3-chloro-5H-dibenzo[b,f]azepine
39607-90-4

3-chloro-5H-dibenzo[b,f]azepine

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
With methanol; magnesium at 50℃; for 1.5h;95%
3-chloro-10,11-dihydro-dibenzo[b,f]azepine-5-carbaldehyde

3-chloro-10,11-dihydro-dibenzo[b,f]azepine-5-carbaldehyde

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
With sodium hydroxide In dimethyl sulfoxide at 75℃; for 0.5h; Yield given;
4-chloro-2-nitrotoluene
89-59-8

4-chloro-2-nitrotoluene

copper-powder

copper-powder

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: N-bromosuccinimide, benzoyl peroxide / CCl4 / 28 h / Heating
2: 5 h / Heating
3: 83 percent / NaH / 1,2-dimethoxy-ethane / 2 h / Heating
4: 82 percent / H2, morpholine / 5 percent Rh/C / ethanol; methanol / 4 h / 18100.2 Torr / Ambient temperature
5: 81 percent / HCOONa / 3 h / Heating
6: K2CO3, Cu, CuBr / dimethylsulfoxide / 3 h / 160 °C
7: 5 N aq. NaOH / dimethylsulfoxide / 0.5 h / 75 °C
View Scheme
4-chloro-2-nitrobenzyl bromide
52311-59-8

4-chloro-2-nitrobenzyl bromide

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 5 h / Heating
2: 83 percent / NaH / 1,2-dimethoxy-ethane / 2 h / Heating
3: 82 percent / H2, morpholine / 5 percent Rh/C / ethanol; methanol / 4 h / 18100.2 Torr / Ambient temperature
4: 81 percent / HCOONa / 3 h / Heating
5: K2CO3, Cu, CuBr / dimethylsulfoxide / 3 h / 160 °C
6: 5 N aq. NaOH / dimethylsulfoxide / 0.5 h / 75 °C
View Scheme
2-[2-(2-bromo-phenyl)-ethyl]-5-chloro-phenylamine
223787-53-9

2-[2-(2-bromo-phenyl)-ethyl]-5-chloro-phenylamine

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 81 percent / HCOONa / 3 h / Heating
2: K2CO3, Cu, CuBr / dimethylsulfoxide / 3 h / 160 °C
3: 5 N aq. NaOH / dimethylsulfoxide / 0.5 h / 75 °C
View Scheme
1-[(E)-2-(2-Bromo-phenyl)-vinyl]-4-chloro-2-nitro-benzene

1-[(E)-2-(2-Bromo-phenyl)-vinyl]-4-chloro-2-nitro-benzene

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 82 percent / H2, morpholine / 5 percent Rh/C / ethanol; methanol / 4 h / 18100.2 Torr / Ambient temperature
2: 81 percent / HCOONa / 3 h / Heating
3: K2CO3, Cu, CuBr / dimethylsulfoxide / 3 h / 160 °C
4: 5 N aq. NaOH / dimethylsulfoxide / 0.5 h / 75 °C
View Scheme
4-chloro-2-nitrobenzylphosphonic acid diethyl ester
52311-60-1

4-chloro-2-nitrobenzylphosphonic acid diethyl ester

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 83 percent / NaH / 1,2-dimethoxy-ethane / 2 h / Heating
2: 82 percent / H2, morpholine / 5 percent Rh/C / ethanol; methanol / 4 h / 18100.2 Torr / Ambient temperature
3: 81 percent / HCOONa / 3 h / Heating
4: K2CO3, Cu, CuBr / dimethylsulfoxide / 3 h / 160 °C
5: 5 N aq. NaOH / dimethylsulfoxide / 0.5 h / 75 °C
View Scheme
N-{2-[2-(2-bromo-phenyl)-ethyl]-5-chloro-phenyl}-formamide
223787-58-4

N-{2-[2-(2-bromo-phenyl)-ethyl]-5-chloro-phenyl}-formamide

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: K2CO3, Cu, CuBr / dimethylsulfoxide / 3 h / 160 °C
2: 5 N aq. NaOH / dimethylsulfoxide / 0.5 h / 75 °C
View Scheme
3-amino-5-acetyl-10,11-dihydro-5H-dibenzazepine
84803-67-8

3-amino-5-acetyl-10,11-dihydro-5H-dibenzazepine

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 85 percent / isoamyl nitrite, CuCl2 / acetonitrile / Ambient temperature
2: 95 percent / KOH / methanol / Heating
View Scheme
clomipramine hydrochloride
17321-77-6

clomipramine hydrochloride

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
With horseradish peroxidase type VI; dihydrogen peroxide In water at 25℃; for 11h; Enzymatic reaction;
3-chloro-5-(3-dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(6,5)azepine
25961-11-9

3-chloro-5-(3-dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(6,5)azepine

A

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

B

ethanol
64-17-5

ethanol

C

C16H16ClN

C16H16ClN

Conditions
ConditionsYield
With Mo2((1)-H)2(OtBu)6; diphenylsilane In toluene at 111℃; for 25h; Inert atmosphere; Schlenk technique;
bromochlorobenzene
106-39-8

bromochlorobenzene

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: caesium carbonate; triphenylphosphine; palladium diacetate; potassium iodide / N,N-dimethyl-formamide / 46 h / 105 °C / Schlenk technique; Inert atmosphere
2: N,N-dimethyl-formamide / 24 h / 130 °C / Schlenk technique; Inert atmosphere
3: magnesium; methanol / 1.5 h / 50 °C
View Scheme
2-bromoaniline
615-36-1

2-bromoaniline

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: caesium carbonate; triphenylphosphine; palladium diacetate; potassium iodide / N,N-dimethyl-formamide / 46 h / 105 °C / Schlenk technique; Inert atmosphere
2: N,N-dimethyl-formamide / 24 h / 130 °C / Schlenk technique; Inert atmosphere
3: magnesium; methanol / 1.5 h / 50 °C
View Scheme
C19H16ClN

C19H16ClN

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 24 h / 130 °C / Schlenk technique; Inert atmosphere
2: magnesium; methanol / 1.5 h / 50 °C
View Scheme
C20H23BClNO2

C20H23BClNO2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
With water; sodium hydroxide In tetrahydrofuran at 25℃; for 1h; Inert atmosphere; Schlenk technique; Sealed tube;0.18 g
chloropropionic acid
107-94-8

chloropropionic acid

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

C17H17Cl2N*ClH

C17H17Cl2N*ClH

Conditions
ConditionsYield
Stage #1: chloropropionic acid With sodium tetrahydroborate In toluene at 0 - 5℃;
Stage #2: 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine With sodium tetrahydroborate In toluene at 25 - 80℃; for 7h;
Stage #3: With hydrogenchloride In water; isopropyl alcohol
99%
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

3-dimethylaminopropionic acid
6300-04-5

3-dimethylaminopropionic acid

clomipramine hydrochloride
17321-77-6

clomipramine hydrochloride

Conditions
ConditionsYield
Stage #1: 3-dimethylaminopropionic acid With sodium tetrahydroborate In toluene at 0 - 5℃;
Stage #2: 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine With sodium tetrahydroborate In toluene at 25 - 80℃; for 5h;
Stage #3: With hydrogenchloride In water; isopropyl alcohol
98%
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

allyl bromide
106-95-6

allyl bromide

3-chloro-5-(prop-2-enyl)-10,11-dihydro-5H-dibenzo[b,f]azepine
1425793-87-8

3-chloro-5-(prop-2-enyl)-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
Stage #1: 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine With sodium hydride In N,N-dimethyl-formamide; mineral oil at 20℃; for 0.333333h; Inert atmosphere;
Stage #2: allyl bromide In N,N-dimethyl-formamide; mineral oil at 20℃; for 1h; Inert atmosphere;
97%
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

chloroacetyl chloride
79-04-9

chloroacetyl chloride

2-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethanone
726140-60-9

2-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethanone

Conditions
ConditionsYield
In toluene at 100℃; for 1h;93%
In toluene at 100℃; for 1h;87%
In toluene for 12h; Heating;53%
In toluene Heating;
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

iodobenzene
591-50-4

iodobenzene

C20H16ClN

C20H16ClN

Conditions
ConditionsYield
With nickel(II) oxide; potassium tert-butylate; triphenylphosphine In tetrahydrofuran at 100℃; for 24h; Inert atmosphere; Sealed tube; Green chemistry;90%
With potassium tert-butylate; copper(II) oxide In dimethyl sulfoxide at 80℃; for 18h; Reagent/catalyst; Inert atmosphere;83%
With potassium tert-butylate; copper(II) oxide In dimethyl sulfoxide at 80℃; for 18h; Solvent; Sealed tube; Inert atmosphere;83%
bromobenzene
108-86-1

bromobenzene

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

C20H16ClN

C20H16ClN

Conditions
ConditionsYield
With nickel(II) oxide; potassium tert-butylate; triphenylphosphine In tetrahydrofuran at 100℃; for 24h; Inert atmosphere; Sealed tube; Green chemistry;90%
With potassium tert-butylate; copper(II) oxide In dimethyl sulfoxide at 80℃; for 18h; Reagent/catalyst; Inert atmosphere;86%
With potassium tert-butylate; copper(II) oxide In dimethyl sulfoxide at 80℃; for 18h; Solvent; Sealed tube; Inert atmosphere;86%
2-bromoacetyl chloride
22118-09-8

2-bromoacetyl chloride

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

2-bromo-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethan-1-one

2-bromo-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethan-1-one

Conditions
ConditionsYield
In toluene at 100℃; for 1h;90%
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

2-Bromo-m-xylene
576-22-7

2-Bromo-m-xylene

3-chloro-N-(2,6-dimethylphenyl)iminodibenzyl

3-chloro-N-(2,6-dimethylphenyl)iminodibenzyl

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 100℃; for 16h; Inert atmosphere;89%
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

epichlorohydrin
106-89-8

epichlorohydrin

3-chloro-5-(oxiran-2-ylmethyl)-10,11-dihydro-5H-dibenzo[b,f]azepine
1423078-41-4

3-chloro-5-(oxiran-2-ylmethyl)-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
Stage #1: 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine With n-butyllithium In tetrahydrofuran; hexane at -78℃; for 0.333333h; Inert atmosphere;
Stage #2: epichlorohydrin In tetrahydrofuran; hexane at 20℃; for 23h;
88%
Stage #1: 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine With n-butyllithium at -15 - -10℃; for 0.666667h; Inert atmosphere; Large scale;
Stage #2: epichlorohydrin at -25 - -20℃; for 1h; Inert atmosphere; Enzymatic reaction; Large scale; Further stages;
72%
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

2-chloropropionyl chloride
625-36-5

2-chloropropionyl chloride

3-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one

3-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one

Conditions
ConditionsYield
In toluene at 100℃; for 4h;87%
In toluene at 100℃; for 1h;68%
With sodium hydroxide In methanol; ethyl acetate; toluene4.0 g (57%)
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

methanesulfonic acid 4-(tert-butoxycarbonyl-methyl-amino)-butyl ester
99230-20-3

methanesulfonic acid 4-(tert-butoxycarbonyl-methyl-amino)-butyl ester

tert-butyl [4-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butyl]methylcarbamate

tert-butyl [4-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butyl]methylcarbamate

Conditions
ConditionsYield
Stage #1: 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0 - 20℃; for 1h;
Stage #2: methanesulfonic acid 4-(tert-butoxycarbonyl-methyl-amino)-butyl ester In N,N-dimethyl-formamide; mineral oil at 0 - 55℃;
86%
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

chlorobenzene
108-90-7

chlorobenzene

C20H16ClN

C20H16ClN

Conditions
ConditionsYield
With potassium tert-butylate; copper(II) oxide In dimethyl sulfoxide at 80℃; for 18h; Inert atmosphere;85%
With potassium tert-butylate; copper(II) oxide In dimethyl sulfoxide at 80℃; for 18h; Solvent; Sealed tube; Inert atmosphere;85%
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

N,N-dimethyl-3-bromopropylamine
53929-74-1

N,N-dimethyl-3-bromopropylamine

Clomipramine
303-49-1

Clomipramine

Conditions
ConditionsYield
Stage #1: 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine With sodium hydride In tetrahydrofuran at 110℃; for 2h; Glovebox; Inert atmosphere; Schlenk technique;
Stage #2: N,N-dimethyl-3-bromopropylamine In tetrahydrofuran at 110℃; for 22h; Glovebox; Inert atmosphere; Schlenk technique;
66%
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

2-(4-bromobutyl)isoindoline-1,3-dione
5394-18-3

2-(4-bromobutyl)isoindoline-1,3-dione

2-[4-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butyl]-1H-isoindole-1,3(2H)-dione

2-[4-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butyl]-1H-isoindole-1,3(2H)-dione

Conditions
ConditionsYield
Stage #1: 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0℃; for 1h;
Stage #2: 2-(4-bromobutyl)isoindoline-1,3-dione In N,N-dimethyl-formamide; mineral oil at 55℃; for 4h;
58%
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

methanesulfonic acid 2-(tert-butoxycarbonyl-methyl-amino)propyl ester
273756-96-0

methanesulfonic acid 2-(tert-butoxycarbonyl-methyl-amino)propyl ester

tert-butyl 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl(methyl)carbamate

tert-butyl 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl(methyl)carbamate

Conditions
ConditionsYield
Stage #1: 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine With lithium hexamethyldisilazane In tetrahydrofuran at 0 - 20℃; for 0.75h;
Stage #2: methanesulfonic acid 2-(tert-butoxycarbonyl-methyl-amino)propyl ester In tetrahydrofuran at 75℃; for 5h;
55%
sodium cyanide
773837-37-9

sodium cyanide

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

3-cyano-iminodibenzyl
66834-19-3

3-cyano-iminodibenzyl

Conditions
ConditionsYield
With nickel(II) bromide trihydrate In 1-methyl-pyrrolidin-2-one at 200℃; for 0.5h; Microwave irradiation;33%
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

(1S,9aR)-1-(chloromethyl)octahydro-2H-quinolizine
34298-00-5

(1S,9aR)-1-(chloromethyl)octahydro-2H-quinolizine

3-Chloro-5-[(1R,9aR)-1-(octahydro-quinolizin-1-yl)methyl]-10,11-dihydro-5H-dibenzo[b,f]azepine; hydrochloride

3-Chloro-5-[(1R,9aR)-1-(octahydro-quinolizin-1-yl)methyl]-10,11-dihydro-5H-dibenzo[b,f]azepine; hydrochloride

Conditions
ConditionsYield
With sodium amide 1.) xylene, reflux, 1 h, 2.) xylene, reflux, 4 h; Yield given. Multistep reaction;
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

(1S,9aR)-1-(aminomethyl)-(octahydro-2H-quinolizine)
23506-89-0

(1S,9aR)-1-(aminomethyl)-(octahydro-2H-quinolizine)

3-Chloro-5-[(1S,9aR)-1-(octahydro-quinolizin-1-yl)methyl]-10,11-dihydro-5H-dibenzo[b,f]azepine

3-Chloro-5-[(1S,9aR)-1-(octahydro-quinolizin-1-yl)methyl]-10,11-dihydro-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
With sodium amide 1.) xylene, reflux, 1 h, 2.) xylene, reflux, 4 h; Yield given. Multistep reaction;
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

1-(3-chloro-10,11-dihydro-dibenzo[b,f]azepin-5-yl)-2-(octahydro-quinolizin-1-ylmethylsulfanyl)-ethanone

1-(3-chloro-10,11-dihydro-dibenzo[b,f]azepin-5-yl)-2-(octahydro-quinolizin-1-ylmethylsulfanyl)-ethanone

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: toluene / Heating
2: ethanol / Heating
View Scheme
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

3-chloro-5-(2-chloroethyl)-10,11-dihydro-5H-dibenz[b,f]azepine
351228-39-2

3-chloro-5-(2-chloroethyl)-10,11-dihydro-5H-dibenz[b,f]azepine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 53 percent / toluene / 12 h / Heating
2: 80 percent / NaBH4; BF3*Et2O / tetrahydrofuran / 3 h / 10 - 20 °C
View Scheme
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

2-(2-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethanol
351228-35-8

2-(2-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethanol

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: 53 percent / toluene / 12 h / Heating
2.1: 80 percent / NaBH4; BF3*Et2O / tetrahydrofuran / 3 h / 10 - 20 °C
3.1: t-BuOK / 1 h / 50 °C
3.2: 56 percent / tetrahydrofuran / 48 h / 150 °C
View Scheme
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

toluene-4-sulfonic acid 2-[2-(3-chloro-10,11-dihydro-dibenzo[b,f]azepin-5-yl)-ethoxy]-ethyl ester

toluene-4-sulfonic acid 2-[2-(3-chloro-10,11-dihydro-dibenzo[b,f]azepin-5-yl)-ethoxy]-ethyl ester

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: 53 percent / toluene / 12 h / Heating
2.1: 80 percent / NaBH4; BF3*Et2O / tetrahydrofuran / 3 h / 10 - 20 °C
3.1: t-BuOK / 1 h / 50 °C
3.2: 56 percent / tetrahydrofuran / 48 h / 150 °C
4.1: n-butyllithium / hexane; tetrahydrofuran / 0.25 h / 0 °C
4.2: hexane; tetrahydrofuran / 0.5 h / 20 °C
View Scheme
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

1-{2-[2-(3-chloro-10,11-dihydro-dibenzo[b,f]azepin-5-yl)-ethoxy]-ethyl}-piperidine-3-carboxylic acid

1-{2-[2-(3-chloro-10,11-dihydro-dibenzo[b,f]azepin-5-yl)-ethoxy]-ethyl}-piperidine-3-carboxylic acid

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1.1: 53 percent / toluene / 12 h / Heating
2.1: 80 percent / NaBH4; BF3*Et2O / tetrahydrofuran / 3 h / 10 - 20 °C
3.1: t-BuOK / 1 h / 50 °C
3.2: 56 percent / tetrahydrofuran / 48 h / 150 °C
4.1: n-butyllithium / hexane; tetrahydrofuran / 0.25 h / 0 °C
4.2: hexane; tetrahydrofuran / 0.5 h / 20 °C
5.1: K2CO3 / acetone / 120 h / 20 °C
6.1: aq. NaOH / ethanol / 20 °C
View Scheme
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
32943-25-2

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

1-{2-[2-(3-chloro-10,11-dihydro-dibenzo[b,f]azepin-5-yl)-ethoxy]-ethyl}-piperidine-3-carboxylic acid ethyl ester

1-{2-[2-(3-chloro-10,11-dihydro-dibenzo[b,f]azepin-5-yl)-ethoxy]-ethyl}-piperidine-3-carboxylic acid ethyl ester

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: 53 percent / toluene / 12 h / Heating
2.1: 80 percent / NaBH4; BF3*Et2O / tetrahydrofuran / 3 h / 10 - 20 °C
3.1: t-BuOK / 1 h / 50 °C
3.2: 56 percent / tetrahydrofuran / 48 h / 150 °C
4.1: n-butyllithium / hexane; tetrahydrofuran / 0.25 h / 0 °C
4.2: hexane; tetrahydrofuran / 0.5 h / 20 °C
5.1: K2CO3 / acetone / 120 h / 20 °C
View Scheme

32943-25-2Relevant articles and documents

Reactive metabolites of desipramine and clomipramine: The kinetics of formation and reactivity with DNA

Korobkova, Ekaterina A.,Nemeth, John,Cadougan, Mikeisha,Venkatratnam, Abhishek,Bassit, Mohanram,Azar, Nikolay

, p. 340 - 345 (2012)

Tricyclic antidepressants (TCAs), along with phenothyazines and some industrial chemicals, are shown to react with enzymes that exhibit peroxidase activity. These reactions result in the formation of reactive intermediates having unpaired electrons. The peroxidase oxidation and reactivity of two TCAs, desipramine and clomipramine, were investigated. As a model of peroxidase, horseradish peroxidase (HRP) was employed. The products of the peroxidase catalyzed oxidation of desipramine and clomipramine were identified as N-dealkylated compounds iminodibenzyl and 3-chloroiminodibenzyl using the GC/MS technique. Both drugs formed broad UV/vis absorption spectra in the presence of HRP and H2O2, indicating the formation of a radical cations - reactive intermediate of the oxidation reaction. The dynamics of the formation of the desipramine intermediate was studied using UV/vis spectroscopy. The extinction coefficient was measured for the reactive intermediate, 7.80 × 103 M-1 cm-1, as well as the apparent Michaelis-Menten and catalytic constants, 4.4 mM and 2.3 s-1, respectively. Both desipramine and clomipramine degraded DNA in the presence of HRP/H2O2, as was revealed by agarose gel electrophoresis and PCI extraction. Manipulating the kinetic parameters of drug's radical formation and determining the extent of degradation to biomolecules could be potentially used for designing effective agents exhibiting specific reactivity.

High-purity clomipamine hydrochloride and preparation method thereof

-

Paragraph 0082; 0089; 0094-0096; 0106; 0110-0111; 0118; 0122, (2020/11/23)

The invention relates to high-purity clomipamine hydrochloride and a preparation method thereof. Specifically, the preparation method comprises the following steps: reacting bromochloropropane with dimethylamine in the presence of alkali to obtain an intermediate I compound; adding 3-chlor-5-acetyl diphenyl imide and potassium hydroxide into toluene, and heating for reaction to obtain an intermediate II; adding potassium carbonate, potassium hydroxide into the intermediate II, and heating reactants, then adding a mixed solution of the intermediate I compound and methylbenzene, continuously heating to finish the reaction, then cooling the reaction solution, and adding water for extraction to obtain an organic layer containing clomipamine; concentrating the previous product under reduced pressure to obtain an oily substance, adding acetone, dropwise adding hydrochloric acid for acidification, crystallizing, centrifuging to obtain a crystal, and drying to obtain a clomipamine hydrochloride crude product; and adding the obtained clomipamine hydrochloride crude product and a solvent into a reaction kettle, heating for dissolving, adding medicinal carbon for reflux decolorization treatment, filtering for decarburization, cooling for crystallization, filtering for crystallization, and drying to obtain a clomipamine hydrochloride finished product. The method has the effects described in the specification.

Enhancing Reactivity and Selectivity of Aryl Bromides: A Complementary Approach to Dibenzo[b,f]azepine Derivatives

Casnati, Alessandra,Fontana, Marco,Coruzzi, Giovanni,Aresta, Brunella Maria,Corriero, Nicola,Maggi, Raimondo,Maestri, Giovanni,Motti, Elena,Della Ca', Nicola

, p. 4346 - 4352 (2018/09/14)

Dihydrodibenzo[b,f]azepines and dibenzo[b,f]azepines can be efficiently synthesized from aryl bromides, o-bromoanilines and norbornene or norbornadiene by means of palladium catalysis. This protocol gives access to dibenzo[b,f]azepine core containing a variety of electron-withdrawing substituents on both aromatic rings and complements the previously reported methodology where electron rich aryl iodides were preferentially used. The presence of KI, even in sub-stoichiometric amount, is crucial for this three-component reaction. The proper addition of iodide anions has a dramatic effect on reaction rate and selectivity. A formal three-step synthesis of the tricyclic antidepressant Clomipramine (Anafranil) is also described.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 32943-25-2